In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on
the cell surface, which provided the immune system with the signal to detect and eliminate …

Purpose: Although the efficacy of programmed cell death–1 (PD-1) blockade is generally
poor for non–small cell lung cancer (NSCLC) with activating mutations of the epidermal …

Immunotherapy has been incorporated into the first-and second-line treatment strategies for
non-small cell lung cancer (NSCLC), profoundly ushering in a new treatment landscape …

Highlights•Current cancer therapy targets both the tumor and the immune system.•Tumor
microenvironment (TME) regulates the anti-tumor immune responses.•Tumor-infiltrating …

Abstract Background Cancer-associated fibroblasts (CAFs) in the tumour microenvironment
(TME) suppress antitumour immunity, and the tyrosine kinase inhibitor nintedanib has …

Background Neoantigen (NeoAg) peptides displayed at the tumor cell surface by human
leukocyte antigen molecules show exquisite tumor specificity and can elicit T cell mediated …